Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q3 EPS by 2c; Authorizes $20M Buyback

Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $37.4 million versus the consensus estimate of $37.5 million.

SciClone announced that its Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $20 million of its outstanding common stock over 24 months.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ball Corporation (BALL) Raises Dividend, Enters 40M Share Buyback, Announces Management Changes
• CVB Financial (CVBF) Tops Q1 EPS by 1c
• Impinj (PI) Tops Q1 EPS by 11c, provides guidance